
RCEL Stock Forecast & Price Target
RCEL Analyst Ratings
Bulls say
AVITA Medical is on track for long term success as evidenced by the stabilizing and broadening growth of its single product, the RECELL system, in addition to its expanding global presence and positive clinical trial results for its Cohealyx product. With strong financial metrics, including a significant increase in guidance, and a favorable risk/reward, AVITA Medical is a strong investment option in the medical industry. However, potential risks such as regulatory and legal factors, as well as competition in the market, should be carefully considered.
Bears say
AVITA Medical is a high-risk investment due to its heavy reliance on a single product, the RECELL system, for its revenue. Despite FDA approval and acceptance in US burn centers, the company has not been able to successfully market the product globally, leading to limited sales and an overall negative outlook for future growth and profitability. Furthermore, the company's contract with BARDA for rapid deployment in burn mass casualty incidents may provide short-term revenue, but the majority of the $25.5M is discretionary and subject to BARDA's exercise, creating additional uncertainty for investors.
This aggregate rating is based on analysts' research of AVITA Medical Inc and is not a guaranteed prediction by Public.com or investment advice.
RCEL Analyst Forecast & Price Prediction
Start investing in RCEL
Order type
Buy in
Order amount
Est. shares
0 shares